Long COVID Atlas
Text Theme

Biology · Viral persistence

Tissue / plasma SARS-CoV-2 RNA

The idea that the virus can hide in the body and keep causing trouble is no longer fringe. Studies have found SARS-CoV-2 RNA in many tissue types months after recovery, and detecting it is strongly associated with having long COVID symptoms. This is some of the most consequential biology in the field, and it is still an association rather than a proven cause.

SARS-CoV-2 RNA persists across many tissues for months in some people, and its detection is strongly linked to long COVID symptoms (OR 5.17). Strong association; causation is the open question.

Start here: the virus can stay

The airway clears, yet RNA can linger in tissuebrain: RNA detected to ~230 daysairway: virus clearedgut, plus 8 other tissue typestissue RNA associated with symptoms (OR 5.17)
Viral RNA detected across multiple tissues; detection associated with symptoms (OR 5.17).

Recovery was once assumed to mean the virus was gone. Tissue studies have overturned that assumption for a subset of people. SARS-CoV-2 RNA has been found persisting in many organ types well after the acute illness, and at autopsy it was detected throughout the body, including the brain, months after symptom onset.

Most importantly, a cross-sectional study found that detecting residual viral RNA was strongly associated with having long COVID symptoms. The link between a measurable reservoir and the lived illness is what makes persistence a central hypothesis.

moderate gradesymptom association OR 5.17association, causation unproven

Where the virus was found

In one cohort, viral RNA was detected across roughly ten different solid tissue types, including stomach, intestine, liver, kidney, brain, blood vessel, and lung, at one, two, and four months after mild infection. A subset even had viral RNA in blood components.

An autopsy study separately mapped the virus across the body and brain, finding RNA persisting in multiple sites long after onset. Together these show that persistence is not confined to one organ but can be widely distributed in the people who have it. The autopsy work skewed toward people who had severe disease, while the tissue-RNA cohort followed mild infections, so persistence is not confined to the sickest and can follow even an unremarkable acute illness.

The symptom link

The pivotal finding is not just that virus persists, but that persistence tracks with illness. In the tissue cohort, people with detectable viral RNA were several times more likely to report long COVID symptoms, and those with higher viral copy numbers were more likely still.

A dose-response pattern, more virus, more likely symptoms, strengthens a causal reading without proving it. It is the kind of relationship that makes persistence a leading candidate driver rather than an incidental laboratory finding.

dose-response with symptoms

What RNA does and does not tell us

A key caution: detecting viral RNA is not the same as detecting whole, infectious, replicating virus. RNA can persist as fragments or as part of a low-level smouldering infection, and the studies cannot always tell these apart, though some found replication signals.

So persistence of RNA is firmly established, while the nature of that persistence, active infection versus inert remnant, is less settled. This distinction matters because only an active reservoir would be expected to respond to antiviral treatment.

Why it could cause symptoms

A persistent reservoir offers a unified explanation for much of long COVID. Ongoing viral material could keep the immune system activated, sustain inflammation, drive clotting changes, and provoke autoimmunity, tying together symptoms across many organs.

That explanatory power is why persistence anchors several treatment ideas, from antivirals to immune approaches. It also raises the stakes: if a reservoir drives the illness, clearing it could help, which is precisely what antiviral trials in long COVID are testing.

What it means for you now

There is no validated test that tells an individual whether they harbour a meaningful reservoir, and a research finding of tissue RNA does not currently change treatment. Persistence testing offered outside trials should be approached with caution.

What this evidence does provide is validation and direction. The virus can stay, its presence tracks with symptoms, and the trials that follow from this hypothesis are among the most watched in the field. That is a reason for grounded hope rather than for buying an unproven test or treatment.

What we don't know

Honest about the edges of the evidence. These are open questions, not settled answers.

  • Whether persistent viral RNA reflects active infection or inert remnants.
  • Whether antivirals that target persistence improve long COVID symptoms.
  • Which tissues matter most and which patients harbour a reservoir.
  • How persistence drives downstream inflammation, clotting, and autoimmunity.
  • How to detect a meaningful reservoir non-invasively in clinic.
  • Why some people clear the virus completely and others do not.

What this means for you

The evidence that SARS-CoV-2 can persist across many tissues for months, and that its detection is strongly associated with long COVID symptoms, is some of the most important biology in the field. If you suspected the virus never fully left, this gives that a real foundation.

It is still an association, and detecting RNA is not the same as proving active infection or a cause. Whether clearing a reservoir helps is what antiviral trials are testing. Be cautious about persistence testing or treatments offered outside research.

References

Each reference links to the source on PubMed, PMC, or the publisher.

  1. Zuo W et al. Persistence of SARS-CoV-2 in tissues and association with long COVID symptoms. Lancet Infect Dis 2024.
  2. Stein SR et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 2022.

Associated topics